Cell and gene therapies (CGTs) are rapidly gaining popularity as proof-of-concept data becomes available. This has resulted in an increase in the number of biotech companies that are investing in developing their own products. With five different cell and gene therapies gaining FDA approval in 2023 alone, there has been a steady influx of potentially life-changing treatments for patients with a wide range of disease indications.1
Although cell and gene therapies may have the potential to revolutionise the pharmaceutical market, they are still relatively novel and come with unavoidable and complex challenges that must be overcome; these extend all the way from discovery to commercialisation. Therefore, outsourcing manufacturing has become increasingly appealing for CGT developers, who are beginning to outsource the process to contract development and manufacturing organisations (CDMOs).
With so many CDMOs offering a range of services at different price points, quality levels and development timeframes, picking a suitable partner can be a daunting experience for any biopharma organisation — small or large. So, what makes a good CDMO? To find out, Annabel Kartal-Allen spoke with Andrew Frazer, Associate Director of Scientific Solutions at Charles River Laboratories.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.